Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Jounce & Redx Pharma Join to Prioritize RXC007 Cancer Treatment

Jounce & Redx Pharma Join to Prioritize RXC007 Cancer Treatment

27th February 2023

Clinical stage biotech firm Redx concentrates its attentions on identification and development of new, low molecular weight molecules, targeted medicines in cancer care processes, fibrotic disorders, and the recently discovered condition known as cancer-associated fibrosis.

Jounce is an immunotherapy business committed to revolutionising clinical stage cancer therapy by creating medicines that promote immune system defense against tumours and deliver individuals with long-term advantages by using biomarkers.

The combined group’s highest priority will be the development of a potent and selective ROCK2 inhibitor called RXC007, which is currently being assessed.

Together their main focus will be on the advancement of RXC007, a next-generation selective ROCK2 inhibitor that is now being evaluated.

Redx’s Chief Executive Officer, Lisa Anson, explained that “by combining Redx’s proven track record in small molecule drug discovery and development with Jounce’s expertise in biologics and immunotherapy, we will establish a world-class biotech company with a robust pipeline, aimed at developing therapeutics for cancer and fibrotic disease.”

“RXC007, our next-generation ROCK2 inhibitor, will lead the clinical pipeline.”

Jounce’s Chief Executive Officer, Richard Murray, expressed that, “with a focus on cancer and fibrosis, and a strong scientific basis for discovery and development programs in those areas, we believe that the new company will be well positioned to succeed.”

Total market worth for the merged group is projected to be $425 million given Redx’s fully diluted stock value of $294 million and Jounce’s most liquid current assets.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.